AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16860974 — intervention group
Group type: EXPERIMENTAL
Intervention: Definition 2 (BPRS % change, CGI-S threshold score maintained for at least 8 weeks)
Number of subjects: 0
Study 16860974 — intervention group
Group type: EXPERIMENTAL
Intervention: Both definitions (patients meeting threshold criteria at both 24 and 52 weeks)
Number of subjects: 0
Study 16860974 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS total % change from baseline
Number of subjects: 0
Study 16860974 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients meeting threshold criteria at the 8-, 16-, or 24-week visits
Number of subjects: 0
Study 12787711 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 0
Study 12787711 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose escalation
Number of subjects: 0
Study 12787711 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy
Number of subjects: 0
Study 12787711 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation following surgery
Number of subjects: 0
Study 12787711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation and dose individualisation
Number of subjects: 0
Study 11186159 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonemic fluency tests administered individually
Number of subjects: 0
Study 11186159 — intervention group
Group type: COMPARATOR
Intervention: Healthy normal controls
Number of subjects: 0
Study 8761394 — intervention group
Group type: COMPARATOR
Intervention: Cleansing enema
Number of subjects: 150
Study 8761394 — intervention group
Group type: EXPERIMENTAL
Intervention: Pico-salax
Number of subjects: 150
Study 8761394 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely
Number of subjects: 150
Study 1486111 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized study
Number of subjects: 0
Study 1486111 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized study
Number of subjects: 0
Study 3514333 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil (250 mg once a day)
Number of subjects: 32
Study 3514333 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 3514333 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil
Number of subjects: 32
Study 31897748 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 58
Study 31897748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercises
Number of subjects: 58
Study 31897748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 29066327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vaccine candidate (n = 7)
Number of subjects: 12
Study 29066327 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 12
Study 28086004 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery‐Asberg Depression Rating Scale (MADRS) with a 24‐hour recall period (MADRS‐24hr)
Number of subjects: 23
Study 28086004 — intervention group
Group type: EXPERIMENTAL
Intervention: MADRS‐24hr
Number of subjects: 23
Study 24387663 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher-completed delivery mode
Number of subjects: 201
Study 24387663 — intervention group
Group type: COMPARATOR
Intervention: Self-completed delivery mode
Number of subjects: 201
Study 24387663 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient questionnaires
Number of subjects: 201
Study 24387663 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated dates from patient questionnaires
Number of subjects: 201
Study 22751375 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula enriched with fish oil
Number of subjects: 40
Study 22751375 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control formula
Number of subjects: 40
Study 20197658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention, energy restricted by 30% for 8 weeks
Number of subjects: 324
Study 20197658 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline leptin concentrations
Number of subjects: 324
Study 20197658 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention
Number of subjects: 324
Study 18394859 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency electrical stimulation of the subthalamic nucleus
Number of subjects: 15
Study 18394859 — intervention group
Group type: COMPARATOR
Intervention: Stimulation turned off
Number of subjects: 15
Study 20015816 — intervention group
Group type: COMPARATOR
Intervention: 0.0625% bupivacaine alone (Group A)
Number of subjects: 60
Study 20015816 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine + 2 microg/mL fentanyl (Group B)
Number of subjects: 60
Study 20015816 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine + 4 microg/mL fentanyl (Group C)
Number of subjects: 60
Study 16526414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy product intake
Number of subjects: 0
Study 16526414 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11762412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituxan (rituximab) in combination with CHOP chemotherapy
Number of subjects: 0
Study 11762412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituxan (rituximab)
Number of subjects: 0
Study 9394690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.03 mg vitamin B-6/d
Number of subjects: 16
Study 9394690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.33 mg vitamin B-6/d
Number of subjects: 16
Study 9394690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.73 mg vitamin B-6/d
Number of subjects: 16
Study 9394690 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.39 mg vitamin B-6/d
Number of subjects: 16
Study 9394690 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.84 mg vitamin B-6/d
Number of subjects: 16
Study 9394690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.14 mg vitamin B-6/d
Number of subjects: 16
Study 9394690 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.34 mg vitamin B-6/d
Number of subjects: 16
Study 8110669 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar block (group R)
Number of subjects: 450
Study 8110669 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular anaesthesia (group PI)
Number of subjects: 450
Study 8110669 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular anaesthesia (group PII)
Number of subjects: 450
Study 3828178 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lignocaine 160 mg using a Forrester Spray
Number of subjects: 30
Study 3828178 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lignocaine 160 mg by 'Laryng‐o‐jet'
Number of subjects: 30
Study 3828178 — intervention group
Group type: COMPARATOR
Intervention: Saline administered by Forrester Spray
Number of subjects: 30
Study 12510954 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6-12 mg/day
Number of subjects: 725
Study 12510954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study 30223772 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hand disinfection
Number of subjects: 25
Study 30223772 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing surgical gloves
Number of subjects: 25
Study 30223772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial growth at glove cuff end
Number of subjects: 25
Study 30223772 — intervention group
Group type: COMPARATOR
Intervention: Total colony forming units
Number of subjects: 25
Study 26679760 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus T3 (25 μg daily)
Number of subjects: 32
Study 26679760 — intervention group
Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 32
Study 23564056 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine based on heparin concentration measured after CPB (Group 2)
Number of subjects: 30
Study 23564056 — intervention group
Group type: COMPARATOR
Intervention: Protamine dose based on initial heparin dose (Group 1)
Number of subjects: 30
Study 22415336 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of saturated fat
Number of subjects: 1261
Study 22415336 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of additional whole-grain bread (50 g/1000 kcal)
Number of subjects: 1261
Study 22415336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of dietary fiber (g/1000 kcal)
Number of subjects: 1261
Study 20428109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 21
Study 20428109 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 21
Study 19137768 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of doxycycline taken twice daily
Number of subjects: 100
Study 19137768 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of doxycycline taken twice daily
Number of subjects: 100
Study 15990606 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone replacement therapy (HRT)
Number of subjects: 214
Study 15990606 — intervention group
Group type: COMPARATOR
Intervention: Control group (never received HRT)
Number of subjects: 214
Study 12421059 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological priming paradigm
Number of subjects: 0
Study 12421059 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified standard priming experiment
Number of subjects: 0
Study 10624544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (1200 mg)
Number of subjects: 16
Study 10624544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8749685 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin light chains from hemodialysis patients
Number of subjects: 0
Study 8749685 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin light chains from continuous ambulatory peritoneal dialysis patients
Number of subjects: 0
Study 8749685 — intervention group
Group type: COMPARATOR
Intervention: Free immunoglobulin light chains
Number of subjects: 0
Study 2045522 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia gum
Number of subjects: 0
Study 2045522 — intervention group
Group type: COMPARATOR
Intervention: Sugar-free gum
Number of subjects: 0
Study 6989592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy (dietary intensive care, Biguanides, Clofibrate)
Number of subjects: 150
Study 6989592 — intervention group
Group type: COMPARATOR
Intervention: Routine method (control group)
Number of subjects: 150
Study 31498154 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 138
Study 31498154 — intervention group
Group type: COMPARATOR
Intervention: Combined NBI and Indigo Carmine Chromoendoscopy (ICC)
Number of subjects: 138
Study 29885068 — intervention group
Group type: EXPERIMENTAL
Intervention: Nangibotide (1 mg, 10 mg, and doses ranging from 0.03 to 6 mg kg-1 h-1)
Number of subjects: 27
Study 29885068 — intervention group
Group type: EXPERIMENTAL
Intervention: Nangibotide (various doses)
Number of subjects: 27
Study 27289490 — intervention group
Group type: EXPERIMENTAL
Intervention: 500IR
Number of subjects: 355
Study 27289490 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR
Number of subjects: 355
Study 27289490 — intervention group
Group type: EXPERIMENTAL
Intervention: 100IR
Number of subjects: 355
Study 27289490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 25052595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous voriconazole (100 mg two times per day until neutrophils greater than 0.5×10⁹/L)
Number of subjects: 227
Study 25052595 — intervention group
Group type: COMPARATOR
Intervention: Oral fluconazole (200 mg per day)
Number of subjects: 227
Study 25052595 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival comparison between patients with or without IFD
Number of subjects: 227
Study 25052595 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IFD incidence between voriconazole and fluconazole groups
Number of subjects: 227
Study 25052595 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver function abnormalities
Number of subjects: 227
Study 25052595 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory hallucination and visual impairment due to voriconazole
Number of subjects: 227
Study 22613649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine (600 mg intravenous infusion once a day for a month, then 200 mg oral capsule three times a day)
Number of subjects: 65
Study 22613649 — intervention group
Group type: COMPARATOR
Intervention: Control group (silibin meglumine tablet only, same method and dosage as treatment group)
Number of subjects: 65
Study 20955605 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (supervised aerobic interval training sessions, one hour, up to three times weekly)
Number of subjects: 60
Study 20955605 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 60
Study 18946302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine and 2 microg/ml fentanyl (group BF)
Number of subjects: 32
Study 18946302 — intervention group
Group type: COMPARATOR
Intervention: 0.1% bupivacaine (group B)
Number of subjects: 32
Study 16096533 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (200, 100, and 100 microg/kg)
Number of subjects: 301
Study 16096533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 12756490 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 32400
Study 12756490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 32400
Study 12756490 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E combination
Number of subjects: 32400
Study 12756490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32400
Study 10739391 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 5 ppm
Number of subjects: 0
Study 10739391 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 10 ppm
Number of subjects: 0
Study 10739391 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 40 ppm
Number of subjects: 0
Study 10739391 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 5, 10, and 40 ppm
Number of subjects: 0
Study 8737211 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 301
Study 8737211 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 301
Study 1533479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 0
Study 1533479 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 0
Study 1533479 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine
Number of subjects: 0
Study 1533479 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous administration of hepatitis B vaccine, BCG, and inactivated polio vaccine
Number of subjects: 0
Study 3909373 — intervention group
Group type: EXPERIMENTAL
Intervention: RP 40 749
Number of subjects: 6
Study 3909373 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 6
Study 30789910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine prophylaxis for patients with CD4 <200 cells/μL
Number of subjects: 54
Study 30789910 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis for patients with CD4 ≤200 cells/μL
Number of subjects: 54
Study 28952009 — intervention group
Group type: EXPERIMENTAL
Intervention: Information pack
Number of subjects: 32
Study 28952009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information pack)
Number of subjects: 32
Study 28952009 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with more than one sweat test
Number of subjects: 32
Study 27101823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) intervention over 8 weeks
Number of subjects: 418
Study 27101823 — intervention group
Group type: COMPARATOR
Intervention: Waitlist usual care regimen (control)
Number of subjects: 418
Study 24005641 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect optical laryngoscopy (Airtraq, Prodol, Spain)
Number of subjects: 24
Study 24005641 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy (McGrath, Aircraft Medical, UK)
Number of subjects: 24
Study 24005641 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy (Macintosh blade #3)
Number of subjects: 24
Study 23127215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/vegetable juice
Number of subjects: 2397
Study 23127215 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole fruits/vegetables
Number of subjects: 2397
Study 20484945 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 78
Study 20484945 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 18405245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (group TAC)
Number of subjects: 212
Study 18405245 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (group MMF)
Number of subjects: 212
Study 15809382 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0.1 mg/kg)
Number of subjects: 63
Study 15809382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 63
Study 12433703 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant alleles at XRCC1 codon 194
Number of subjects: 260
Study 12433703 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant alleles at XRCC1 codon 399
Number of subjects: 260
Study 12433703 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant at XRCC1 codon 280
Number of subjects: 260
Study 12433703 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for common allele at codon 399 with low dietary intake of vitamin E
Number of subjects: 260
Study 12433703 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for common allele at codon 399 with low dietary intake of lycopene
Number of subjects: 260
Study 12433703 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intake of vitamin C, A, or beta‐carotene
Number of subjects: 260
Study 9435325 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide
Number of subjects: 20
Study 9435325 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide + Estradiol or Progesterone
Number of subjects: 20
Study 9435325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8003644 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 million units of lymphoblastoid IFN-alpha daily for 2 weeks
Number of subjects: 80
Study 8003644 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of lymphoblastoid IFN-alpha daily for 2 weeks
Number of subjects: 80
Study 8003644 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million units of lymphoblastoid IFN-alpha daily for 2 weeks
Number of subjects: 80
Study 8003644 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 80
Study 2809902 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionyl growth hormone, 2 IU/m2 subcutaneously once daily (group 1)
Number of subjects: 30
Study 2809902 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionyl growth hormone, 4 IU/m2/day (group 1B)
Number of subjects: 30
Study 2809902 — intervention group
Group type: COMPARATOR
Intervention: Authentic biosynthetic growth hormone (group 2)
Number of subjects: 30
Study 2809902 — intervention group
Group type: COMPARATOR
Intervention: No therapy (group 3)
Number of subjects: 30
Study 1106217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium combined with major tranquilizers
Number of subjects: 22
Study 1106217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31746743 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (Agent)
Number of subjects: 125
Study 31746743 — intervention group
Group type: COMPARATOR
Intervention: Standard drug-coated balloon (SeQuent Please)
Number of subjects: 125
Study 29448235 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational app
Number of subjects: 96
Study 29448235 — intervention group
Group type: COMPARATOR
Intervention: Cartoon
Number of subjects: 96
Study 27746555 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (500 μg/kg IV bolus followed by 100 μg/kg/min infusion)
Number of subjects: 60
Study 27746555 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg IV bolus followed by 0.2 μg/kg/h infusion)
Number of subjects: 60
Study 27746555 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% IV)
Number of subjects: 60
Study 24750511 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior pedicle reduction mammoplasty
Number of subjects: 67
Study 24750511 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resection weight
Number of subjects: 67
Study 24750511 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 67
Study 24750511 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 67
Study 24750511 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 67
Study 24750511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 67
Study 24750511 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smoked
Number of subjects: 67
Study 22678104 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-α-lipoic acid (LA) supplementation
Number of subjects: 62
Study 22678104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 20599163 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple paclitaxel-eluting stents (n=50)
Number of subjects: 184
Study 20599163 — intervention group
Group type: COMPARATOR
Intervention: Single paclitaxel-eluting stents (n=134)
Number of subjects: 184
Study 20599163 — intervention group
Group type: COMPARATOR
Intervention: Single paclitaxel-eluting stents (n=20)
Number of subjects: 184
Study 20599163 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple paclitaxel-eluting stents (n=10)
Number of subjects: 184
Study 20599163 — intervention group
Group type: COMPARATOR
Intervention: Single paclitaxel-eluting stents
Number of subjects: 184
Study 20599163 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple paclitaxel-eluting stents
Number of subjects: 184